Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systemic Lupus Erythematosus (Sle) Clear all
Completed No phase listed Observational Results available

Implementing the Decision-Aid for Lupus (IDEAL Strategy)

NCT03735238
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
SMILE Computerized Decision-Aid
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
1,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jun 25, 2026, 8:49 PM EDT
Completed Not applicable Interventional

Prevention of Arthritis-Related Work Disability

NCT00000416
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Knee, Ankylosing Spondylitis
Interventions
Rehabilitation counseling
Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Jun 25, 2026, 8:49 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

NCT00624338
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Atacicept 75 mg, Atacicept 150 mg, Placebo Comparator
Drug · Other
Lead sponsor
EMD Serono
Industry
Eligibility
16 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Jun 25, 2026, 8:49 PM EDT
Completed Phase 2 Interventional

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

NCT01162681
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
A-623, Placebo Comparator
Drug · Other
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Jun 25, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

NCT01261793
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, Epratuzumab
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
791 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Hemet, California + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Jun 25, 2026, 8:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

NCT03949426
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
KPG-818
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jun 25, 2026, 8:49 PM EDT
Recruiting No phase listed Observational

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

NCT06659029
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
Female only
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 25, 2026, 8:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus

NCT01269866
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Cymbalta
Drug
Lead sponsor
Dr. Jesus Gutierrez Stone
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Jun 25, 2026, 8:49 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

NCT06935474
View directory record Official record
Conditions
Lupus Nephritis (LN)
Interventions
C-CAR168
Biological
Lead sponsor
AbelZeta Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jun 25, 2026, 8:49 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

NCT02041091
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Tabalumab Auto-Injector, Tabalumab Prefilled Syringe
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
36
States / cities
Covina, California • El Cajon, California • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Jun 25, 2026, 8:49 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

NCT00381810
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
11
States / cities
Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jun 25, 2026, 8:49 PM EDT
Terminated Phase 1 Interventional Results available

Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

NCT00684255
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Reduced Intensity Allogeneic Transplant, Fludarabine, Busulfan, Campath
Procedure · Drug
Lead sponsor
New York Medical College
Other
Eligibility
7 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Jun 25, 2026, 8:49 PM EDT
Completed Phase 1 Interventional

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

NCT00774943
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
AMG 557
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Anniston, Alabama • Phoenix, Arizona • San Leandro, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Jun 25, 2026, 8:49 PM EDT
Recruiting Phase 2 Interventional

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

NCT05268289
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Fontana, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 25, 2026, 8:49 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

NCT00775476
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 25, 2026, 8:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

NCT05508009
View directory record Official record
Conditions
SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
Interventions
Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg, Total Body Irradiation, ATG, Rituximab, Melphalan, CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Kidney Transplant
Drug · Radiation · Device + 1 more
Lead sponsor
Alice Bertaina
Other
Eligibility
1 Year to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Jun 25, 2026, 8:49 PM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
BI 3000202, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 74 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
31
States / cities
Beverly Hills, California • La Palma, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 25, 2026, 8:49 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

NCT06625671
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
Interventions
DB-2304, Placebo, Prednisone
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
6
States / cities
La Palma, California • Clearwater, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 25, 2026, 8:49 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Obinutuzumab, Placebo, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
14
States / cities
Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 25, 2026, 8:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance

NCT01180361
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2025
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jun 25, 2026, 8:49 PM EDT
Completed Phase 2 Interventional Results available

Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

NCT02270957
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jun 25, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients

NCT02119156
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Manhasset, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Jun 25, 2026, 8:49 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

NCT06544330
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
Interventions
SYNCAR-001, STK-009
Drug
Lead sponsor
Synthekine
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2041
U.S. locations
5
States / cities
Scottsdale, Arizona • Hackensack, New Jersey • Manhasset, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jun 25, 2026, 8:49 PM EDT
Completed Phase 3 Interventional Results available

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

NCT01262365
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab, Placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Jun 25, 2026, 8:49 PM EDT